Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference

Rhea-AI Summary

Nuvalent, a clinical-stage biopharmaceutical company specializing in targeted cancer therapies, announced its participation in the 2024 Jefferies Global Healthcare Conference. The event will feature a fireside chat with CEO James Porter and CFO Alexandra Balcom on June 5, 2024, at 4:30 p.m. ET. The session will be live-streamed and available on the company's website for 30 days.

Positive

• Participation in a prestigious event like the Jefferies Global Healthcare Conference enhances Nuvalent's visibility in the industry.
• Involvement of top executives (CEO and CFO) indicates strong representation and potential strategic discussions.
• Live webcast availability may broaden investor access leading to increased engagement.

Negative

• No new clinical or financial data was presented, leaving investors without new actionable insights.
• Potential shareholder concerns due to lack of immediate, concrete updates on pipeline progress or financial performance.

CAMBRIDGE, Mass., May 29, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 4:30 p.m. ET in NYC.

A live webcast will be available in the Investors section of the company's website at www.nuvalent.com, and archived for 30 days following the presentation.

About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-participate-in-the-2024-jefferies-global-healthcare-conference-302157212.html

SOURCE Nuvalent, Inc.

FAQ

What did Nuvalent announce on May 29, 2024?

Nuvalent announced its participation in the 2024 Jefferies Global Healthcare Conference, featuring a fireside chat with CEO James Porter and CFO Alexandra Balcom.

When will Nuvalent's fireside chat take place during the 2024 Jefferies Global Healthcare Conference?

The fireside chat will take place on June 5, 2024, at 4:30 p.m. ET.

How can investors access Nuvalent's presentation at the 2024 Jefferies Global Healthcare Conference?

Investors can access the live webcast of Nuvalent's presentation through the Investors section of the company's website.

Will the webcast of Nuvalent's presentation at the 2024 Jefferies Global Healthcare Conference be available after the event?

Yes, the webcast will be archived on the company's website for 30 days following the presentation.